Taken together, our findings reveal the role of PirB/LILRB2 in NASH pathogenesis and identify PirB/LILRB2-ANGPTL8 signaling as a potential target for the management or treatment of NASH. The gene discussed is LILRB2; the disease is metabolic dysfunction-associated steatohepatitis.